Alport Syndrome clinical trials at University of California Health

3 in progress, 2 open to eligible people

Showing trials for

  • An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

    open to eligible people ages 12 years and up

    This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

    at UCLA UCSF

  • Atrasentan in Patients With Proteinuric Glomerular Diseases

    open to eligible people ages 18 years and up

    The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

    at UCLA

  • Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

    Sorry, in progress, not accepting new patients

    Primary Objectives: - To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function - To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: - To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites - To assess the potential formation of anti-drug antibodies (ADAs) following administration of lademirsen (SAR339375) - To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes in renal injury and function biomarkers.

    at UCLA

Our lead scientists for Alport Syndrome research studies include .

Last updated: